President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare ProfessionalsDiabetes Information & Resources
Clinical Research50-Year Medalist Study
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowGet InvolvedEventsTributes & Special OccasionsCorporate & Foundation EngagementLegacy GivingWays to GivePhilanthropy TeamPublications

Om P. Ganda, M.D.


A Co-Investigator in the landmark Diabetes Control and Complications Trial (DCCT), completed in 1993, Om P. Ganda, MD, has been engaged in clinical diabetes research for more than three decades. The DCCT demonstrated the importance of glucose control in preventing complications in type 1 diabetes. Dr. Ganda is now a Co-Investigator of Epidemiology of Diabetes Intervention and Complications (EDIC), an ongoing long-term follow-up study. This study continues to unravel  long-term benefits of  optimal  glucose control .

In addition to his clinical research and teaching, Dr. Ganda directs the Lipid Center at Joslin, where he treats patients with elevated cholesterol and triglycerides. He is also studying why patients with Type 2 diabetes have increased susceptibility to elevated lipid particles and cardiovascular disease . He is a Co-Investigator of several ongoing clinical trials to identify better ways to treat people who have difficulty with exercise and diet control. The goal is to find better treatments that will control not only cholesterol and triglycerides (as statins do), but also blood pressure and blood glucose.

Page last updated: September 19, 2019